Polo‐like kinase2 regulates renal tubulointerstitial fibrosis via notch signaling pathway in diabetic kidney disease

作者：Jiayi Luo, Haibin Xu, Cailin Su, Wenhui Dong, Manlu Xiao, Nan Xiao, Yijie Jia, Yaoming Xue · 发表于：The FASEB Journal · 年份：2025 · DOI：10.1096/fj.202402793r · 被引用次数：7 · 研究领域：Renal cell carcinoma treatment、Renal and Vascular Pathologies、Genetic and Kidney Cyst Diseases

Renal tubulointerstitial fibrosis is considered as an important pathological feature of diabetic kidney disease (DKD). However, the underlying mechanism remains unclear. Polo-like kinase2 (PLK2) is a known player in the regulation of organ fibrosis. Herein, we investigated the expression and function of PLK2 in renal tubular epithelial cells in DKD. Data from the GSE30529 datasets were subjected to analyze the differentially expressed genes (DEGs) in non-diabetic and diabetic renal tubule samples. Molecular docking analysis and Co-IP assay were performed to investigate the interaction between PLK2 and NOTCH1. Immunohistochemistry, immunofluorescent staining, qRT-PCR, and western blot were performed. Our research revealed an increased expression of PLK2 in both DKD mouse kidney tissues and HK-2 cells stimulated by high glucose (HG). Silencing PLK2 remarkably reduced the expression of the renal fibrosis-related markers fibronectin (FN), connective tissue growth factor (CTGF) and alpha smooth muscle actin(αSMA). Furthermore, we verified the interaction between PLK2 and NOTCH1. Silencing PLK2 significantly inhibited the activation of the Notch signaling pathway, and concurrently overexpressing HES1 rescued the downregulation of FN, CTGF, and αSMA induced by transfecting si-PLK2. Finally, we found that treatment with DAPT suppressed the activation of the Notch signaling pathway and reversed the progression of renal fibrosis caused by HG. This study demonstrates that PLK2 mediates ...